SYS-CON MEDIA Authors: Peter Silva, Unitiv Blog, RealWire News Distribution, Kevin Benedict, PR.com Newswire

News Feed Item

AKESOgen and the VA Million Veteran Program to Collaborate on Genotyping 105,000 Veterans

AKESOgen announced today that it has been awarded a $7.5M contract by the U.S. Department of Veterans Affairs (VA) for genotyping samples from U.S. veterans as part of the Million Veteran Program (MVP). This award covers the genotyping of 105,000 veterans in the first year of a five-year contract.

“The VA’s Million Veteran Program is one of the largest genetic initiatives ever undertaken in the U.S. and its visionary genomics and genetics approach will provide new insights about how genes affect health. The goal is to improve healthcare for veterans by understanding the genetic basis of many common conditions. The data will ultimately be beneficial to the healthcare of all veterans and of the wider community. We are delighted to have been selected by the VA for this unique endeavor and we will provide genetic data of the highest quality to the VA,” said Bob Boisjoli, CEO of AKESOgen. To fulfill the VA contract, AKESOgen will utilize a custom-designed, array-based genotyping solution from Affymetrix, Inc.

“We are honored to be part of the MVP project by providing our Axiom Genotyping Solution to support the VA’s goal of building one of the largest genetic databases in order to improve healthcare for our veterans,” commented Dr. Frank Witney, President and CEO of Affymetrix.

AKESOgen provides genomics services for the research and development market, including biobanking, DNA/RNA extraction, and genetic technologies. Founded in 2010, the company services the clinical, pharmaceutical, biotechnology, academic, and government sectors.

To learn more about AKESOgen, please visit www.akesogen.com.

About AKESOgen, Inc.

AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

About the VA Million Veteran Program

Launched in 2011, MVP is a landmark research effort aimed at better understanding how genes affect health. Up to a million Veterans are expected to enroll in the VA study over the next 5-6 years. Data and genetic samples collected through the study are stored securely and made available for studies by authorized researchers, with stringent safeguards in place to protect Veterans’ private health information. MVP is now enrolling at over 50 VA medical centers nationwide. The VA’s central bio-repository is equipped with a state-of-the-art robotic system for DNA extraction and storage and is currently being expanded to support up to 4 million samples. With more than 240,000 enrollees to date, MVP already far exceeds the enrollment numbers of any single VA study or research program in the past.

MVP provides researchers with a rich resource of genetic, health, lifestyle, and military-exposure data collected from questionnaires, medical records, and genetic analyses. By combining this information into a single database, MVP promises to advance knowledge about the complex links between genes and health.

Veterans’ privacy and confidentiality are top priorities in MVP, as in all VA research. For more information about MVP, visit www.research.va.gov/MVP.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.